A Lyon-based biotech developing KDX-350, an oral bivalent CK2 inhibitor for colorectal and clear-cell renal cancer, to license to a pharmaceutical partner from 2027.
This overview is generated using artificial intelligence based on information available
on the platformโs project page and publicly accessible data. It is provided for
informational purposes only and does not constitute investment advice, financial
guidance, risk assessment, or project scoring. Platforms and project owners are not
involved in the creation, review, or endorsement of this content.
AI project overview
Condensed summary based on project data
<p><span style="font-size:28pt"><span style="font-family:"Times New Roman",serif">Kairos Discovery — Crowdfunding Investor Memo</span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>A French laboratory company designing an experimental cancer medicine that it plans to sell or license to a large pharmaceutical company rather than sell to patients itself.</em></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Sector: </strong>Biotechnology (preclinical oncology)<strong> · Stage: </strong>Seed (preclinical)<strong> · HQ: </strong>Lyon, France<strong> · Raise: </strong>€850,000 target (maximum €1,500,000)</span></span></p>
<h1><span style="font-size:16pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">Snapshot</span></span></span></h1>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f0f4f8; border-bottom:#dce2e8; border-left:#c8cfd8; border-right:#dce2e8; border-top:#c8cfd8; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">1 · Is the price fair? ๐ถ</span></strong></span></span></p>
</td>
<td style="background-color:#d9ebc2; border-bottom:1px solid #dce2e8; border-left:none; border-right:1px solid #c8cfd8; border-top:1px solid #c8cfd8; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">5 / 5 </span></strong><span style="color:black">— Supported. At €2.8M–€3.3M before this round, the price is below every European early-stage benchmark we located: a median of €5.0M in Q3 2025 and €3.6M over the longer term (PitchBook-derived data, November 2025), a typical seed range of €4M–€12M (Startkeel, 2026), and a European early-stage median of $6.54M for 2020–2025 (Equidam, Q3 2025).</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f0f4f8; border-bottom:1px solid #dce2e8; border-left:1px solid #c8cfd8; border-right:1px solid #dce2e8; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">2 · Can they reach an exit stage? โญ</span></strong></span></span></p>
</td>
<td style="background-color:#faece7; border-bottom:1px solid #dce2e8; border-left:none; border-right:1px solid #c8cfd8; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE 63 / 100 — Average</span></strong></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The strongest evidence is the people and the science: the chairman led a comparable Lyon company to an acquisition by Eli Lilly in 2023, and the underlying research is published in a peer-reviewed chemistry journal with a crystal structure deposited in a public database. The biggest gap is that the medicine being offered here, KDX-350, is not the compound described in that publication, and no data on KDX-350 itself is in the pack we reviewed.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f0f4f8; border-bottom:1px solid #c8cfd8; border-left:1px solid #c8cfd8; border-right:1px solid #dce2e8; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">3 · If they do, what could it pay? ๐ฏ</span></strong></span></span></p>
</td>
<td style="background-color:#faece7; border-bottom:1px solid #c8cfd8; border-left:none; border-right:1px solid #c8cfd8; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target 20x over 3.5–4.5 years</span></strong><span style="color:black"> (the company's own plan; the standard expectation for a seed-stage company is about 10x over 5–7 years).</span></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">If reached, illustratively <strong>5x–50x</strong> before fees and before future dilution. Method: the required sale value divided by the €4.09M value of the whole company at this round's price. The low end is a licensing deal at the median upfront payment for a preclinical cancer drug, $22M (Ambrosia Ventures deal database, 2026); the high end is the company's own stated target of more than €200M once the medicine has shown early results in patients.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>How to read the score</strong></span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#d9ebc2; border-bottom:#dce2e8; border-left:#c8cfd8; border-right:#dce2e8; border-top:#c8cfd8; vertical-align:top; width:160px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">85–100 · Excellent</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #dce2e8; border-lef
โฆ
Equity crowdfunding
